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INTRODUCTION: Identification of variables that determine the prognosis for osteosarcoma may enable stratification of patients 
into subgroups with better or worse risk of local recurrence, metastases and death due to the disease. Discovery of such prognostic 
factors would permit selection of a subgroup of at-risk patients, with the aim of improving the therapeutic effectiveness.
OBJECTIVE: To identify prognostic factors related to local recurrence-free survival, metastasis-free survival and overall sur-
vival among patients with highly malignant primary osteosarcoma that was non-metastatic on diagnosis and had poor response to 
neoadjuvant chemotherapy.
SAMPLE AND METHODS: Out of 45 patients admitted to a referral center in Brazil between 2000 and 2004, 24 were selected 
for this study.
RESULTS: The adverse factors that influenced the risk of local recurrence and the overall survival in univariate analysis were 
histological subtype other than osteoblastic (p = 0.017) and tumor size greater than 15 cm (p = 0.048). In relation to metastasis-free 
survival, the non-osteoblastic subtype had a worse prognosis (p = 0.007). The association of histological subtype maintained its 
significance in multivariate analysis for all studied survival categories.
CONCLUSIONS: Tumor size greater than 15 cm is an adverse factor for local recurrence-free survival and overall survival but did 
not influence metastasis-free survival. The osteosarcoma histological type is a significant independent predictor for local recurrence-
free survival, metastasis-free survival and overall survival.
KEYWORDS: Bone neoplasms; Pathology; Epidemiology; Surgery; Drug therapy.
INTRODUCTION
Boyer (1805) apud Mehlman & Cripe (2008)1 was the 
first to use the term “osteosarcoma”, referring to a distinct 
entity apart from more frequent bone lesions. Primary 
tumors affecting bone tissue are comparatively rare among 
neoplasias.2
Osteosarcomas may be primary or secondary. The 
latter are sarcoma forms that occur in bones affected by 
preexisting abnormalities,3 such as Paget’s disease, radiation 
lesions, bone infarct, fibrous dysplasia or osteomyelitis.3-5 
Among primary osteosarcomas, these precursor conditions 
are not observed. 
Primary osteosarcomas are considered to be a disease 
of young people,6 with peak incidence in the second decade 
of life.4,5 Among older children and adolescents (12-18 
years), they are the third most common type of neoplasia, 
preceded by leukemia and lymphoma.7 Their etiology 
remains unknown,4,6 but it is known that the period of 
their greatest incidence coincides with the growth spurt of 
puberty. This period is characterized by rapid growth of the 
long bones, suggesting a correlation between this phase 
1178
CLINICS 2009;64(12):1177-86Prognostic factors in the osteosarcoma
Bispo Júnior RZ et al.
of life and appearance of these tumors.5,8 They may occur 
in any anatomical location. They preferentially affect the 
metaphyses of long bones; the three main sites are the distal 
femur, tibia and proximal humerus.6,9-15
Histologically, osteosarcomas can be classified into several 
types: osteoblastic, chondroblastic, fibroblastic, rich in giant 
cells, epithelioid, small cells and telangiectasic, depending on 
the dominant element. The locations of these lesions in the 
bone are named parosteal, periosteal and intramedullary. The 
conventional type, emerging from the intramedullary cavity, 
represents around 75% of all osteosarcomas.16 
Clinically, these tumors are initially manifested as 
local pain that is generally nonspecific, with or without an 
associated palpable tumor. This presentation may occur over 
periods ranging from weeks to months.4-6,17
Over recent decades, there have been major changes 
in the diagnosis and treatment of these tumors, giving 
rise to significant increases in five-year survival among 
such patients. Formerly, the five-year survival rate was 
approximately 10-25%, but it is now around 50-75%, 
according to American and European studies.7,11,12,18-25 
Brazilian studies10,15,26 have also demonstrated this evolution 
in multidisciplinary therapy, although not reaching the rates 
cited in other countries.
Identification of variables that determine the prognosis 
for osteosarcoma may permit stratification of these patients 
into subgroups with better or worse risk of local recurrence, 
metastasis and death due to this disease. Discovery of such 
prognostic factors would allow at-risk patients to be selected 
with the aim of improving the therapeutic results.
The aim of the present study, which is part of a general 
investigation on sarcomas,27,28 was to identify prognostic 
factors relating to local recurrence-free survival (LRFS), 
metastasis-free survival (MFS) and overall survival (OS) 
among patients with highly malignant primary osteosarcoma 
that was non-metastatic on diagnosis, with a poor response 
to neoadjuvant chemotherapy.
SAMPLE AND METHODS
Inclusion criteria
All of the patients included in the present study 
fulfilled the following eligibility criteria: (a) there was 
anatomopathological confirmation of primary osteosarcoma 
following review of all of the slides by a pathologist 
specializing in musculoskeletal tissues; (b) the patients 
were treated (during this period) with the same neoadjuvant 
chemotherapy protocol (GBTO Study V); (c) the patients 
were operated on at our center to achieve local control over 
the primary tumor following chemotherapy; and (d) the 
patients were considered to present poor responses to the 
preoperative chemotherapy (grades I and II), according to 
the classification of HUVOS et al.29 (1977).
The  med ica l  f i l e s  o f  45  pa t i en t s  w i th  an 
anatomopathological diagnosis of primary osteosarcoma 
made by the Orthopedic Oncology Group at a referral 
center in Brazil between 2000 and 2004 were evaluated. 
These patients had been treated in accordance with the 
recommendations from Study V of the Brazilian Cooperative 
Group for Osteosarcoma Treatment (GBTO). Among these 
45 patients, 19 were excluded from the study because, at the 
time of diagnosis, they presented metastases at the initial 
evaluation. Another two cases were also excluded: one patient, 
with a low degree of malignancy, did not undergo neoadjuvant 
chemotherapy (surface osteosarcoma; parosteal); the other 
patient died before the operation, due to complications from 
the chemotherapy. Thus, the variables in the medical files 
of 24 patients who underwent treatment at our center were 
analyzed. This project was approved by the Research Ethics 
Committee of the participating institution.
Casuistic analysis
Gender and age
Among the 24 patients studied, 14 (58.3%) were male 
and 10 (41.7%) were female, with a proportion of 1.4:1.0. 
Their ages ranged from 5 to 44 years, with a mean of 15.75 
± 7.57 years (median of 15 years). 
Anatomical location
Seventeen (70.8%) of the patients presented with a tumor 
in the femur, particularly in its distal third (Figure 1). Among 
Figure 1 - Magnetic resonance images demonstrating the tumor expansion 
process (osteosarcoma) in the distal metaphysis and epiphysis of the left 
femur and affecting soft tissues (extra-compartmental). Coronal (A) and 
axial (B) T1 images
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the remaining patients, the tibia was affected in four cases 
(16.7%) and the humerus in two (8.3%), all in the proximal 
region. The maxilla was affected in one case (4.2%). The 
knee region (distal femur and proximal tibia) was the most 
frequent location, accounting for 87.5% of the cases. 
Clinical condition and its duration
All of the patients presented clinical complaints of 
local pain, except for the cases of pathological fracture 
(12.5%). The tumor was the most frequent sign. It occurred 
in association with pain in 58.3% of the cases. The time 
between sign or symptom onset and seeking of medical care 
ranged from 0 to 12 months, with a mean of 3.67 +/- 2.81 
months (median of three months) among the patients studied.
Assessment criteria of variables
Epidemiological and clinical variables
Gender - male or female;
Age - less than or equal to 15 and greater than 15 years old 
(median);
Anatomical location - local presentation was divided into 
the femur or extra-femur;
Clinical condition - two groups were formed: with or 
without pathologic fracture;
Delay of clinical condition - less than to 3 and greater than 
or equal to three months (median).
Anatomopathological variables
Histological type - osteoblastic or non-osteoblastic variants; 
Tumor size - less than or equal to 15 and greater than 15 
cm;10
Surgical margins - less than or equal to 2 and greater than 
2mm (mean).
Therapeutic variables
Surgical treatment – tumor resection was wide or radical.30
Statistical analysis
Relevant medical data was extracted from medical 
files, using a defined protocol, and assembled in a database 
(Excel 2007, Windows software). Statistical analyses were 
performed using SPSS statistical software (Version 12.0; 
SPSS Inc., Chicago, IL, USA). 
Descriptive analysis was performed using means, 
medians and percentages. The simple frequencies of all 
of the studied variables were calculated. The accumulated 
survival chances were determined using the Kaplan-Meier 
technique. All of the variables were analyzed with regard to 
their importance for the prognoses of LRFS, MFS and OS.
We simplified the numbers by means of standardized 
rounding techniques, with elimination of the decimal places 
for the frequencies and survival rates. Multivariate analysis 
was performed using the logistic regression technique, with 
the Cox proportional hazards model. Statistical significance 
was defined as p < 0.05.
RESULTS
Epidemiological and clinical variables
Pulmonary metastasis
Pulmonary metastasis was identified in nine patients 
(37%). All of them developed pulmonary metastasis 
after they had been diagnosed with osteosarcoma. Eight 
progressed to death after a follow-up ranging from 2 to 54 
months. The eighth patient was still alive with pulmonary 
disease at 17 months after the diagnosis.
Length of follow-up
The mean length of follow-up among the patients with 
non-metastatic osteosarcoma in our sample was 39.08 
months (with a standard deviation of 28.16 months and 
median of 47 months), ranging from 2 to 83 months.
Death due to neoplasia
The death rate consequent to osteosarcoma was 41.7% 
(10 cases).
Anatomopathological variables
Histology and tumor size
The histological type was reviewed by a pathologist after 
surgical resection. The osteoblastic variant was the most 
common histological type, affecting 10 of the 24 cases. 
The case frequencies according to histological subtype 
of osteosarcoma were osteoblastic (41.7%) and non-
osteoblastic (58.3%) (chondroblastic, mixed, telangiectasic, 
round-cell rich and fibroblastic) (Table 1) (Figure 2). 
The tumor size ranged from 4 to 29 cm along its greatest 
dimension, with a mean of 12.26 +/- 6.15 cm (median of 
10.50 cm), according to measurements of the specimens 
after surgical resection. Subsequently, the tumors were 
divided into two groups, according to PETRILLI et al.10 
(1991): less than or equal to 15 cm (78.3%) and greater than 
15 cm (21.7%) (Table 1).
Surgical margins
The width of the free margin of the surgical resection 
(type wide-limb salvage) ranged from 0.10 to 1.00 cm, with 
a mean of 0.26 cm (standard deviation of 0.24) and median 
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of 0.10 cm. In radical resection (ablative), the margins were 
greater.
Therapeutic variables
Surgical and adjuvant treatment
In all cases, the tumor resection was wide (22 cases) 
or radical (2 cases), according to the classification of 
ENNEKING et al.30 (1980). The surgery preserved limbs and 
limb function in the majority of the cases (91.7%) (Figure 
3). The bone material was replaced by unconventional 
endoprostheses in 81.8% of the cases and by allografts in 
18.2% (Figure 4). All of the patients received preoperative 
chemotherapy in accordance with the recommendations 
from GBTO Study V [with cisplatin (120 mg/m2/cycle), 
ifosfamide (13.5 g/m2/cycle) and adriamicin (80 mg/m2/
cycle), totaling nine cycles for patients who were non-
metastatic at diagnosis].
Local recurrence
Local recurrence was observed in two cases (8.3%), both 
of which were non-osteoblastic. These two patients (100%) 
with local recurrence presented pulmonary metastases and 
progressed to death.
Prognostic factors relating to local recurrence-free 
survival
The LRFS curve for the 24 patients is presented in 
Figure 5. The LRFS rates for these patients were 61% and 
55%, respectively, for two and five years. The factors that 
influenced the risk of local recurrence in the univariate 
analysis were tumor size (p = 0.048) and histological 
Figure 2 - Photomicrograph showing the telangiectasia type of osteosarcoma 
(non-osteoblastic) (200 X- HE)
Table 1 - Distribution of select anatomopathological variables 
for the 24 patients with primary osteosarcoma that was non-
metastatic at diagnosis
   
Variable Category Frequency 
(n)
Percent (%) 
Histological Type Osteoblastic (O) 10 41.7
Chondroblastic (C) 5 20.8
Fibroblastic 1 4.2
Mixed (O + C) 3 12.5
Round-cell rich 1 4.2
Telangiectasic 2 8.3
Not classifiable 2 8.3
Tumor Size* (cm) ≤ 15 18 78.3
> 15 5 21.7
* Data available for 23 patients.
Figure 3 - Intraoperative photograph showing a wide tumor resection in the 
distal region of the left femur
Figure 4 - Radiograph showing a lateral view of the knee region, in which 
osteoarticular substitution using an unconventional modular endoprosthesis 
can be seen
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subtype (p = 0.017). The presence of a tumor measuring 
more than 15 cm along its greatest axis was considered to 
be an adverse factor. Subtypes that were considered to be 
non-osteoblastic presented a greater local recurrence rate 
than did the osteoblastic types. The survival curves for the 
variables with statistical significance (histological type and 
tumor size) are presented in Figures 6 and 7.
The other studied factors did not reach statistical 
significance (gender, age, tumor location, clinical condition 
and duration, surgical margins and type of surgical 
treatment).
Multivariate analysis was performed using the Cox 
proportional hazards logistic regression model to evaluate 
the risk of local recurrence. For this analysis, the variables 
of histological type and tumor size were used, since these 
variables reached p < 0.10 in the univariate analysis (Kaplan-
Meier curve). We applied a stepwise variable selection 
process to the model and observed that histological type was 
associated with LRFS. Thus, the risk that a patient with local 
recurrence would not survive was 8.4 times greater when the 
histological type was non-osteoblastic.
Prognostic factors relating to metastasis-free survival
The MFS curve for the 24 patients is presented in Figure 8. 
The MFS rates for these patients were 57% and 51% for two 
and five years, respectively. Histological subtype was the only 
factor that influenced the risk of metastasis in the univariate 
analysis (p = 0.007). The non-osteoblastic subtype presented 
a higher rate of metastasis than did the osteoblastic subtype. 
The survival curve for the variable presenting statistical 
significance (histological type) is shown in Figure 9.
The other factors did not reach statistical significance 
(age, gender, tumor location, clinical condition and duration, 
tumor size, surgical margins and type of surgical treatment).
Figure 5 - Curve of local recurrence-free survival in months for the 24 
patients with primary osteosarcoma that was non-metastatic at diagnosis
Figure 6 - Curve of local recurrence-free survival in months for the 24 
patients with primary osteosarcoma that was non-metastatic at diagnosis, 
according to histological type
Figure 7 - Curve of local recurrence-free survival in months for the 23 
patients with primary osteosarcoma that was non-metastatic at diagnosis, 
according to tumor size
Figure 8 - Curve of metastasis-free survival in months for the 24 patients 
with primary osteosarcoma that was non-metastatic at diagnosis
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We observed that the parameter of histological type was 
the only factor that presented statistical significance in the 
multivariate analysis using the Cox regression model for 
MFS. Thus, the risk that a patient presenting pulmonary 
metastasis over the course of the treatment would not survive 
was 10 times greater when the histological type presented 
was non-osteoblastic.
Prognostic factors relating to overall survival
The OS rates for the 24 patients studied were 61% 
and 55% for two and five years, respectively (Figure 
10). The factors that influenced the risk of death in the 
univariate analysis were histological subtype (p = 0.017) 
and tumor size (p = 0.048). The survival curves for the 
variables presenting statistical significance (tumor size and 
histological type) are shown in Figures 11 and 12.
Gender, age, tumor location, clinical condition and 
duration, surgical margins and type of surgical treatment did 
not reach the statistically significant level (p < 0.05).
For the multivariate analysis, we used the variables of 
histological type and tumor size (which presented with p 
< 0.10 in the univariate analysis). We applied a stepwise 
variable selection process to the model and observed that 
histological type was associated with OS. The risk that a 
patient would not survive was 8.4 times greater when the 
histological type was non-osteoblastic.
DISCUSSION
Several clinical studies10,11,13-15,19,25,26,31-43 aiming to 
identify prognostic factors that might influence the survival 
of patients with osteosarcoma have been published. 
However, because of the great variation in the methodology 
Figure 9 - Curve of metastasis-free survival in months for the 24 patients 
with primary osteosarcoma that was non-metastatic at diagnosis, according 
to histological type
Figure 10 - Curve of overall survival in months for the 24 patients with 
primary osteosarcoma that was non-metastatic at diagnosis
Figure 11 - Curve of overall survival in months for the 24 patients with 
primary osteosarcoma that was non-metastatic at diagnosis, according to 
histological type
Figure 12 - Curve of overall survival in months for the 23 patients with 
primary osteosarcoma that was non-metastatic at diagnosis, according to 
tumor size
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used in these studies, the results are inconsistent and it 
is difficult to determine the real prognostic effects of the 
evaluated variables.31
The low frequency of this disease in itself would explain 
our small sample size. In addition, we used several rigid 
inclusion and exclusion criteria in this study with the aims 
of maintaining a homogeneous sample and, thus, faithfully 
evaluating the prognostic factors.
Overall, the age distribution of these tumors was 
bimodal. The first and larger peak of incidence was found 
to occur during the second decade of life.4,5 The second and 
smaller peak was seen among patients over 40-50 years of 
age,3,5 and has been found to be secondary to a preexisting 
bone abnormality.3-5 Classically, patients with primary 
osteosarcoma have been young and male,4,6,10-13,32 and the 
results from our series are concordant with this picture. The 
variables of age25,33,34 and gender33,35 have been shown to be 
prognostic factors in some series using univariate analysis 
alone. However, PETRILLI et al.10 (1991) stated that male 
gender was a poor prognostic factor and FERRARI et 
al.13 (2001) indicated that age significantly influenced the 
survival of their patients in a double analysis (univariate 
and bivariate). In the present study, gender and age were not 
found to be significant prognostic variables, in agreement 
with other studies.19,36
With regard to the anatomical region most affected by 
these tumors, the literature shows that the femur is the most 
frequent site, followed by the tibia and humerus.6,9,10-15,17,32 
In the present study, we also found that these sites were the 
most affected locations. In investigations of the tumor site 
as a prognostic variable, some studies have demonstrated 
that axial tumors have a relatively greater adverse effect 
than do those of the appendicular skeleton.25,37 However, 
our finding with the present series do not agree with those 
findings, most likely because we only had one axial case 
(affecting the maxilla). In relation to the bone, GLASSER 
et al.11 (1992) and PAKOS et al.32 (2009) reported that the 
prognosis for tumors located in the femur was worse. By 
contrast, GOORIN et al.35 (1987) observed a worse prognosis 
for tumors in the humerus. Our data are not in agreement 
with this finding: we did not find that the location of the 
osteosarcoma was an adverse factor, and our result was 
similar to that of many other papers.12,19,22,38
Two literature reviews on prognostic factors for 
osteosarcoma31,39 have stated that age, gender and tumor 
location were not as fully addressed in the literature as 
relevant variables. 
Clinical complaints of pain are frequently encountered. 
This symptom is generally considered a warning, except 
in cases of pathological fracture. In the present series, 
complaints of locally increased volume were associated with 
painful processes in over half of the cases, similar to the 
finding of another Brazilian study.14
In a different series of osteosarcoma cases in the 
literature,11,17,19 the pathological fracture rate ranges from 7 
to 17%, which is compatible with the result of the present 
study (12.5%). In agreement with some studies,11,19 we did 
not observe a worse prognosis for cases with a pathological 
fracture at the initial diagnosis among our samples. 
Among our patients, the mean amount of time that 
elapsed between the first signs and symptoms and seeking 
medical care was approximately four months ranging from 
0 to 12 months. Despite this large range, the length of time 
that had passed between the signs and symptoms did not 
demonstrate a worse prognosis with regard to the studied 
survival parameters. This association was also found in the 
series reported by PETRILLI et al.15 (2006). Other Brazilian 
authors15,17 have also shown higher means than that found in 
studies in other countries.25 These data suggest that the stage 
of the disease at the time of its initial presentation depends 
more on the biological properties of the tumor than on late 
diagnosis.38 Nonetheless, it is important to emphasize that, 
in the present series, only patients who were non-metastatic 
at the time of diagnosis were included.
Adequate follow-up for these patients made it possible to 
identify pulmonary metastasis in about one-third by means of 
thoracic Computed Tomography. The presence of metastases 
is directly related to a worse prognosis regarding survival: 
eight of the nine patients who developed metastatic disease 
died after a period ranging from 2 to 54 months (88.8%).
In the majority of studies,2,10,11,13,14 the osteoblastic 
variant was the most common histological type. The present 
study found the same result. According to some studies, the 
histological type is a strong predictor of LRFS, MFS and OS 
according to both univariate and multivariate analyses.10,13 
The risk that patients with local recurrence would not 
survive was 8.4 times greater when they presented with 
non-osteoblastic tumors. Furthermore, the risk that patients 
with osteosarcoma who developed pulmonary metastases 
would not survive was 10 times greater when they presented 
with non-osteoblastic tumors. However, in disagreement 
with this finding, some papers,19,40,41 with stratification of the 
non-osteoblastic osteosarcoma (into types), demonstrated 
that the subtype differentially influenced prognosis. 
This association was especially true concerning the 
chondroblastic, telangiectasic or fibroblastic type, which had 
a more favorable prognosis than the osteoblastic type. It is 
interesting to note that patients who have a poor response to 
chemotherapy represent the present series.
Contradictory results are present in the literature, 
including in the principal reviews, regarding the correlation 
between tumor size and the prognosis for the patient.31,39 
1184
CLINICS 2009;64(12):1177-86Prognostic factors in the osteosarcoma
Bispo Júnior RZ et al.
The parameters used in different studies (cutoff points) 
and the way of measuring tumor size (from one to three 
dimensions) may be the main reasons for the lack of 
consensus.10,12,13,15,19,25,31,32,39 In the present series, only one-
fifth of the resected osteosarcomas measured more than 
15 cm along their longest axis. However, this minority 
presented worse results in relation to LRFS (p = 0.048) 
and OS (p = 0.048) according to the univariate analysis, 
thereby corroborating the data presented by several other 
studies.10,13,15,33,34,39,42 In our multivariate analysis, this 
prognostic variable (size) did not maintain significance. 
This finding differed from the studies of PETRILLI et al.10,15 
(1991, 2006), despite the different cutoff points used in those 
two studies: 15 and 12 cm, respectively.
Choosing between the type of surgical procedure 
(conservative or ablative) depends on several factors. 
Surgical treatment has now attained a limb preservation rate 
of around 50-80% of the cases.43-45 In the vast majority of 
the cases in the present study (91.7%), surgical procedures 
that preserved the limbs were performed. When bone 
replacements were implanted, allografts were used in 
approximately one-fifth of the cases and unconventional 
endoprostheses were used in the remainder.
The surgical margins examined under the microscope 
were considered adequate, albeit narrow in some cases, 
ranging from 1 to 10 millimeters with a mean of 0.26 cm. 
The margin variable was not shown to be a significant 
prognostic factor in the present study. Narrow margins can 
be explained for surgical procedures. In the majority of 
cases, the limbs were preserved despite the fact that some of 
the tumors were quite large. Importantly, we had a low rate 
of recurrence (8.3%). 
According to the literature, the local recurrence rate 
in osteosarcoma cases ranged from 2 to 10%.11,20,24,46 This 
recurrence rate was also observed for the cases treated by 
Brazilian surgeons, despite the large dimensions of this type 
of tumor at the time of diagnosis in almost all series.10,15 
The five- and ten-year OS rates in GBTO studies III 
and IV were lower than the rates reported by American and 
European studies.15 However, in our study (GBTO Study V), 
one needs to bear in mind that the respective two- and five-
year survival rates of 61% and 55%, respectively, relate to a 
group of individuals with a poor response to chemotherapy 
and who have a tendency towards lower survival rates. 
Nevertheless, the estimated five-year OS rate of study V 
(55%) was greater than that of the preceding two studies (III 
and IV: 50.1%), thus indicating a trend towards improved 
survival among patients with osteosarcoma who were treated 
within our setting.
CONCLUSIONS
In this series, during our follow-up:
1.  Tumor size greater than 15 cm was found to be an ad-
verse factor for LRFS and OS but did not influence the 
MFS.
2.  The histological type of osteosarcoma is a significant 
independent predictor for LRFS, MFS and OS.
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